Boston Scientific (NYSE:BSX) Given Buy (B-) Rating at Weiss Ratings

Key Points

• Boston Scientific's stock was given a "buy (B-)" rating by Weiss Ratings, reinforcing its positive outlook amid mixed analyst opinions.
• The company reported significant year-over-year revenue growth of 22.8%, with earnings per share (EPS) at $0.75 for the last quarter, surpassing estimates.
• Insiders sold over $17 million worth of stock in the last quarter, resulting in a 58.23% decrease in one director's ownership.

Boston Scientific (NYSE:BSX - Get Free Report)'s stock had its "buy (b-)" rating reiterated by Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Several other equities analysts have also recently weighed in on BSX. Erste Group Bank cut shares of Boston Scientific from a "buy" rating to a "hold" rating in a research note on Friday, October 3rd. Jefferies Financial Group reaffirmed a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $125.00 target price on shares of Boston Scientific in a research note on Monday, September 29th. Canaccord Genuity Group lifted their price objective on shares of Boston Scientific from $131.00 to $132.00 and gave the stock a "buy" rating in a research note on Wednesday, October 1st. Finally, Wells Fargo & Company lifted their price objective on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Boston Scientific currently has an average rating of "Buy" and an average target price of $120.71.

Boston Scientific Price Performance

Shares of BSX stock traded up $0.83 on Wednesday, hitting $96.73. 7,135,200 shares of the stock traded hands, compared to its average volume of 7,968,438. The firm has a market cap of $143.33 billion, a price-to-earnings ratio of 57.58, a PEG ratio of 2.33 and a beta of 0.61. Boston Scientific has a 52 week low of $80.64 and a 52 week high of $109.50. The firm has a 50 day simple moving average of $102.53 and a two-hundred day simple moving average of $101.99. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company's revenue was up 22.8% on a year-over-year basis. During the same period last year, the firm earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts predict that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the company's stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director directly owned 2,081 shares of the company's stock, valued at $222,646.19. This represents a 58.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the sale, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $17,972,457 over the last quarter. Insiders own 0.50% of the company's stock.

Institutional Trading of Boston Scientific

Large investors have recently bought and sold shares of the business. FWL Investment Management LLC acquired a new stake in Boston Scientific during the second quarter worth about $26,000. Sound Income Strategies LLC increased its position in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 120 shares during the last quarter. Steph & Co. acquired a new stake in shares of Boston Scientific during the third quarter valued at about $25,000. 1248 Management LLC acquired a new stake in shares of Boston Scientific during the first quarter valued at about $26,000. Finally, Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific during the first quarter valued at about $27,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.